Chronic Myelomonocytic Leukemia Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
P
Recruiting
- Acute Myeloid Leukemia
- +3 more
- Orlando, Florida
- +3 more
2022-03-31
Mar 31, 2022S
Recruiting
- Acute Myeloid Leukemia
- +14 more
- Fludarabine
- +7 more
- Philadelphia, PennsylvaniaThomas Jefferson University
2022-04-07
Apr 7, 2022M
Recruiting
- Acute Bilineal Leukemia
- +8 more
- Azacitidine
- +3 more
- Houston, TexasM D Anderson Cancer Center
2022-04-05
Apr 5, 2022T
Recruiting
- Acute Lymphoblastic Leukemia
- +15 more
- Hematopoietic Cell Transplantation
- +7 more
- Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
2022-04-01
Apr 1, 2022F
Recruiting
- Juvenile Myelomonocytic Leukemia
- +27 more
- CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
- +2 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022K
Active, not recruiting
- Myelodysplastic Syndromes
- +2 more
- Newcastle, New South Wales, Australia
- +10 more
2022-03-29
Mar 29, 2022N
Active, not recruiting
- Acute Myeloid Leukemia
- +9 more
- Carboplatin
- +3 more
- Los Angeles, California
- +5 more
2022-03-30
Mar 30, 2022J
Recruiting
- Acute Myeloid Leukemia
- +2 more
- JNJ-74856665
- +2 more
- Birmingham, Alabama
- +24 more
2022-03-24
Mar 24, 2022H
Recruiting
- Leukemia, Myeloid, Acute
- +5 more
- Duesseldorf, NRW, Germany
- +10 more
2022-03-21
Mar 21, 2022P
Completed
- Myelodysplastic Syndrome
- +2 more
- PF-04449913 (Glasdegib)
- Azacitidine
- Birmingham, Alabama
- +32 more
2022-03-14
Mar 14, 2022R
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +36 more
- Cyclophosphamide
- +4 more
- Buffalo, New YorkRoswell Park Cancer Institute
2022-03-17
Mar 17, 2022D
Active, not recruiting
- Myelodysplastic Syndrome
- +2 more
- GVAX
- +6 more
- Boston, Massachusetts
- +3 more
2022-02-23
Feb 23, 2022F
Recruiting
- Acute Leukemia
- +18 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +8 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022M
Active, not recruiting
- Acute Myeloid Leukemia
- +6 more
- Azacitidine
- +2 more
- Baltimore, Maryland
- +2 more
2022-02-25
Feb 25, 2022F
Not yet recruiting
- Acute Myeloid Leukemia
- +2 more
- Clofarabine
- +4 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-03-07
Mar 7, 2022M
Recruiting
- Chronic Myelomonocytic Leukemia
- +3 more
- Decitabine
- Tagraxofusp-erzs
- Houston, TexasM D Anderson Cancer Center
2022-03-04
Mar 4, 2022R
Not yet recruiting
- Myelodysplastic Syndromes
- +2 more
- (no location specified)
2022-02-17
Feb 17, 2022N
Active, not recruiting
- Anemia
- +3 more
- Epoetin Alfa
- +2 more
- Birmingham, Alabama
- +512 more
2022-03-01
Mar 1, 2022M
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +25 more
- Allogeneic Natural Killer Cell Line NK-92
- +10 more
- Houston, TexasM D Anderson Cancer Center
2022-03-01
Mar 1, 2022C
Active, not recruiting
- Accelerated Phase Chronic Myelogenous Leukemia
- +125 more
- tetanus-CMV fusion peptide vaccine
- laboratory biomarker analysis
- Duarte, CaliforniaCity of Hope Medical Center
2022-02-28
Feb 28, 2022F
Recruiting
- Acute Lymphoblastic Leukemia
- +11 more
- Cyclosporine
- +8 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-02-25
Feb 25, 2022M
Active, not recruiting
- Acute Myeloid Leukemia With Multilineage Dysplasia
- +6 more
- Azacitidine
- Glutaminase Inhibitor CB-839
- Houston, TexasM D Anderson Cancer Center
2022-02-25
Feb 25, 2022C
Active, not recruiting
- Adult Acute Lymphoblastic Leukemia in Remission
- +6 more
- clofarabine
- +5 more
- Duarte, CaliforniaCity of Hope Medical Center
2022-02-17
Feb 17, 2022P
Active, not recruiting
- Acute Myeloid Leukemia
- +2 more
- Salzburg, Austria
- +17 more
2022-02-17
Feb 17, 2022M
Active, not recruiting
- Chronic Myelomonocytic Leukemia
- +4 more
- Cytarabine
- +3 more
- Houston, TexasM D Anderson Cancer Center
2022-02-14
Feb 14, 2022